Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

What is the purpose of this trial?

This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID

Participation Guidelines

Ages: 18 years and older

Gender: Both

Conatus Pharmaceuticals

Dates: 03/09/2017 - 09/30/2018

Last Updated: 03/24/2017

Study HIC#: 2000020013

Get Involved

For more information about this study, contact:
Hong Chau

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Joseph K Lim

Principal Investigator